Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - American Society for Transplantation and Cellular Therapy and Center for International Blood and Marrow Transplant Research

Rising costs of these therapies challenge affordability and access.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.

Molly Schiffer, PharmD, BCOP, discusses the logistical, operational, and financial challenges of delivering cellular therapies in the outpatient setting, focusing on CAR T-cell therapy, TIL therapies, and emerging trends in non-oncology applications.

J Ryan Shaw, PharmD, BCPS, BCOP, CPP, discusses the value of the ASTCT and CIBMTR Tandem Meeting 2025 as a platform for multidisciplinary collaboration, cutting-edge education, and advancing pharmacy practice in transplant and cellular therapy.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, discusses the logistical challenges and interprofessional strategies essential for delivering cellular therapies in outpatient settings, emphasizing the pharmacist's role in improving patient outcomes and addressing health disparities.

Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.

The study results also indicated that graft versus host disease status was associated with non-compliance following bone marrow transplantation.